MAPT and Alzheimer disease: In prior work in our lab, we have shown that the combined ratiometric measure of amyloid and tau pathology (p-tau/Aβ42), was better at determining diagnostic status—cognitively normal, MCI, and AD—than either p-tau or Aβ42 alone (Prakash et al., 2020, Preprint).